Comparison between ultrasound guided triamcinolone (steroid) injection in sacroiliac joint (a joint in the lower back) and oral Etoricoxib (a painkiller) in patients with spondyloarthritis
- Conditions
- Health Condition 1: M458- Ankylosing spondylitis sacral andsacrococcygeal regionHealth Condition 2: M458- Ankylosing spondylitis sacral andsacrococcygeal region
- Registration Number
- CTRI/2024/07/069736
- Lead Sponsor
- INSTITUTE OF NEUROSCIENCES KOLKATA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
i.Patients = 18 years of age
ii.Fulfilling the ASAS classification criteria of Axial Spondyloarthritis 2011.
iii.Active disease defined by Bath ankylosing spondylitis disease activity index (BASDAI) score = 4, or ASDAS = 2.1.
1.Bony ankylosis of sacroiliac joint - Grade 4 sacroilitis according to the modified New York criteria
2.Patients with only peripheral spondyloarthropathy
3.Predominantly Psoriatic arthritis
4.Predominantly Enteropathic arthritis
5.Patients on biologics and JAK inhibitors
6. Allergy to etoricoxib
7. Contraindication to NSAIDs
8. Pregnancy or lactation at the time of study entry
8. Infective sacroiliitis
10. History of corticosteroid injection in the sacroiliac joint within six months before study entry
11. Malignancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease of spinal pain score (VAS 0-10 scale) at 12 weeksTimepoint: 12 weeks
- Secondary Outcome Measures
Name Time Method Any adverse effect in both the armsTimepoint: 12 weeks;ASDAS (Ankylosing Spondylitis Disease Activity Score) improvementTimepoint: 12 weeks;Bath ankylosing spondylitis disease activity index (BASDAI) 50 responseTimepoint: 12 weeks;NSAID index at 12 weeksTimepoint: 12 weeks;Reduction in CRP levels in blood at 12 weeksTimepoint: 12 weeks